Capecitabine: Fulfilling the promise of oral chemotherapy

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 6, 2002, Pages 733-743

  Hwang, Jimmy J ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Thymidine phosphorylase

Indexed keywords

4 N ACETYLDINALINE; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DRUG METABOLITE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PYRIDOXINE; TAXANE DERIVATIVE; TAXOID; TIPIFARNIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRODRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST METASTASIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; REVIEW; STOMACH CANCER; STOMATITIS; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; METABOLISM; METASTASIS; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PRODRUGS;

EID: 0036079395     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.6.733     Document Type: Review

References (66)

1. Patient preferences for oral versus intravenous palliative chemotherapy
2. International Phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
3. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
4. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
5. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
6. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
7. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
8. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
9. Effect of food on the pharmacokinetics of capecitabine and its metabolits following oral administration in cancer patients
10. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients
11. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
12. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
13. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
14. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
15. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized Phase II study
16. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluourouracil failure with metastatic colorectal cancer
17. A Phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy
18. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized Phase III study
19. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large Phase III study
20. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
21. Continuous 5-fluourouracil in the treatment of breast cancer
22. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
23. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
24. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
25. Oral capecitabine is an active and well tolerated primary palliative treatment in patients with metastatic breast cancer who progress after high dose chemotherapy and autologous stem cell support
26. A Phase II study of capecitabine in patients, who relapsed after high dose chemotherapy followed by peripheral blood stem cell transplantation for metastatic breast cancer
27. Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast cancer (MBC)
28. Capecitabine (Xeloda) as treatment after failure to taxanes for metastatic breast cancer
29. Capecitabine: A new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter Phase II Trial
30. A Phase II study of Xeloda (capecitabine) in patients with advanced/metastatic breast carcinoma - The Cooperative Study Group of Capecitabine for Breast Carcinoma
31. A multicenter Phase II trial of Xeloda (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer
32. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
33. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangio-carcinoma, and gall bladder cancer)
34. A Phase II study of capecitabine (Xeloda) in patients with advanced/metastatic gastric carcinoma
35. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy - The Vienna Experience
36. Capecitabine in the treatment of metastatic renal cell carcinoma
37. Characterizing Hand-Foot Syndrome (HFS) caused by capecitabine
38. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine
39. A Retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)
40. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenograft
41. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
42. A Phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
43. A Phase I study of capecitabine and weekly paclitaxel in advanced solid tumors
44. A Phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC)
45. A Phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
46. Results of a large, Phase III trial of Xeloda/Taxotere combination therapy versus Taxotere monotherapy in patients with metastatic breast cancer (MBC)
47. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
48. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
49. Ongoing Phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC)
50. Extended Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line therapy in metastatic colorectal cancer
51. Phase I Study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors
52. Oxaliplatin and capecitabine in advanced colorectal cancer: A dose-finding trial
53. A Phase I trial of capecitabine (CAPE) & oxaliplatin (OHP)
54. Phase II study of capecitabine (CAP) + oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC)
55. Capecitabine in combination with oxaliplatin as first-line therapy for patients with advanced or metastatic colorectal cancer: Preliminary results of an international multicenter Phase II study
56. Phase II trial of capecitabine and carboplatin in patients with newly diagnosed, advanced non-small cell carcinoma of the lung (NSCLC)
57. A Phase II Trial of Capecitabine (X) and Cisplatin (P) in Previously Untreated Advanced Gastric Cancer (AGC)
58. Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
59. Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors
60. A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies
61. 5-fluorouracil radiation sensitization-a brief review
62. Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/Folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer
63. X-Ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
64. Phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer
65. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
66. Body Surface area as a determinant of pharmacokinetics and drug dosing